Control of the specificity of T cell-mediated anti-idiotype immunity by natural regulatory T cells

被引:0
作者
Max Warncke
Maike Buchner
Gudrun Thaller
Anna Dodero
Alla Bulashevska
Dietmar Pfeifer
Jens Timmer
Hendrik Veelken
机构
[1] University Medical Center Freiburg,Department of Hematology/Oncology
[2] University of Freiburg,Department of Physics and Freiburg Center for Data Analysis and Modeling
[3] Leiden University Medical Center,Department of Hematology
来源
Cancer Immunology, Immunotherapy | 2011年 / 60卷
关键词
Idiotype; Lymphoma; Regulatory T cell; FoxP3;
D O I
暂无
中图分类号
学科分类号
摘要
The idiotypes of B cell lymphomas represent tumor-specific antigens. T cell responses induced by idiotype vaccination in vivo are directed predominantly against CDR peptides, whereas in vitro T cells also recognize framework-derived epitopes. To investigate the mechanisms regulating the specificity of idiotype-specific T cells, BALB/c or B10.D2 mice were immunized with mature dendritic cells loaded with H-2Kd-restricted peptides from influenza hemagglutinin, or from shared (J region) or unique (CDR3) structures of the A20 lymphoma idiotype. Antigen-specific T cells were induced in vivo by the CDR3 and influenza epitopes, but not by the J peptide. Gene expression profiling of splenic regulatory T cells revealed vaccination-induced Treg activation and proliferation. Treg activity involved J epitope-dependent IL-10 secretion and functional suppression of peptide-specific effector T cells. Vaccination-induced in vivo proliferation of transgenic hemagglutinin-specific T cells was suppressed by co-immunization with the J peptide and was restored in CD25-depleted animals. In conclusion, Treg induced by a shared idiotype epitope can systemically suppress T cell responses against idiotype-derived and immunodominant foreign epitopes in vivo. The results imply that tumor vaccines should avoid epitopes expressed by normal cells in the draining lymph node to achieve optimal anti-tumor efficacy.
引用
收藏
页码:49 / 60
页数:11
相关论文
共 246 条
[1]  
Stevenson GT(1977)Idiotypic determinants on the surface immunoglobulin of neoplastic lymphocytes: a therapeutic target Fed Proc 36 2268-2271
[2]  
Elliott EV(1999)Complete molecular remissions induced by patient-specific vaccination plus granulocyte–monocyte colony-stimulating factor against lymphoma Nat Med 5 1171-1177
[3]  
Stevenson FK(2006)Phase I trial of a novel intradermal idiotype vaccine in patients with advanced B-cell lymphoma: specific immune responses despite profound immunosuppression Cancer Res 66 4496-4502
[4]  
Bendandi M(1996)Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells Nat Med 2 52-58
[5]  
Gocke CD(1997)Tumor-specific idiotype vaccines in the treatment of patients with B-cell lymphoma—long-term results of a clinical trial Blood 89 3129-3135
[6]  
Kobrin CB(2006)Clinical benefit associated with idiotypic vaccination in patients with follicular lymphoma J Natl Cancer Inst 98 1292-1301
[7]  
Benko FA(2004)Clinical outcome of lymphoma patients after idiotype vaccination is correlated with humoral immune response and immunoglobulin g fc receptor genotype J Clin Oncol 22 4717-4724
[8]  
Sternas LA(2008)Results of a phase 3 trial evaluating safety and efficacy of specific immunotherapy, recombinant idiotype (Id) conjugated to KLH (Id-KLH) with GM-CSF, compared to non-specific immunotherapy, KLH with GM-CSF, in patients with follicular non-hodgkin’s lymphoma (fNHL) Ann Oncol 19 iv101-5704
[9]  
Pennington R(1994)Naive idiotype-specific CD4+ T cells and immunosurveillance of B-cell tumors Proc Natl Acad Sci USA 91 5700-10977
[10]  
Watson TM(1996)Vaccination with syngeneic, lymphoma-derived immunoglobulin idiotype combined with granulocyte/macrophage colony-stimulating factor primes mice for a protective T-cell response Proc Natl Acad Sci USA 93 10972-3865